Clinical trials: Parkinson Disease(PD)
Parkinson's Disease
Detection of A-synuclein Aggregate as Biomarker in Diagnosing Parkinson's Disease at Early Stage by Using Protein Misfolding Cyclic Amplification (PMCA)
The study will investigate the biomarker of a-synuclein aggregate in CSF detected by protein misfolding cyclic amplification (PMCA) and its sensitivity and specificity in diagnosing Parkinson's disease at H-Y stage I and disease…
- Trial name
- NCT04536857
- Testing
- Biomarker assay
- Where
- China
- Volunteers
- healthy volunteers welcome
- Sponsor
- Huashan Hospital
Alzheimer's Dementia, Parkinson Disease(PD)
Eye Gaze Strategies During Facial Emotion Recognition in Neurodegenerative Diseases: Links With Neuropsychiatric Disorders (EYE-ToM Study)
It is commonly admitted that social cognition impairment, like deficit in facial emotion recognition or misinterpretation of others' intentions (Theory of Mind), are associated with social behavior disorders.
- Conditions
- Alzheimer's Dementia, Parkinson Disease(PD), Fronto-Temporal Dementia
- Trial name
- EYE-ToM (NCT04748263)
- Testing
- No intervention. Only survey and normal use of eye-tracking
- Volunteers
- 74 people
- Sponsor
- Centre Hospitalier Princesse Grace
Parkinson's Disease (PD)
Clinical Study of Chemogenetic Gene Therapy With AAV for Parkinson's Disease Using Stereotactic Surgery in the Subthalamic Nucleus
The investigators propose a gene therapy strategy for Parkinson's disease - a chemogenetic inhibition technique to intervene in the abnormal activity of the subthalamic nucleus in Parkinson's patients.
- Trial name
- CGTPD (NCT07533591)
- Testing
- gene therapy
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Rapid Eye Movement Sleep Behavior Disorder
RBD Longitudinal as Prognostic for PD
Purpose - to validate a combination of biological and clinical markers in the rapid-eye-movement (REM) sleep behavior disorder (RBD) population as indicative of the pre-symptomatic stage of Parkinson's disease (PD).
- Trial name
- RBD6YR (NCT00817726)
- Where
- United States
- Volunteers
- 164 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center, Houston
PARKINSON DISEASE (Disorder), Parkinson s Disease
Effects of Accelerated rTMS On Motor and Cognitive Function in Parkinson's Disease
Parkinson's disease (PD) is a brain disorder that causes progressive problems with movement, such as slowness, stiffness, tremor, and difficulty walking. Many people with PD also develop problems with thinking and memory.
- Trial name
- NCT07554833
- Testing
- TMS
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- San Francisco Neurology and Sleep Center
Parkinson's Disease
DBS of the MLR for Gait and Balance Disorders in PD Patients
Gait and balance disorders represent the main motor disability in advanced Parkinson's disease. These symptoms are less or unresponsive to levodopa treatment and are considered to be a contraindication for deep brain stimulation…
- Trial name
- GAITPARK (NCT02931097)
- Testing
- Deep brain stimulation
- Where
- France
- Volunteers
- 6 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Parkinson's Disease
Carbidopa-Levodopa (CD-LD) ER Alone or in Combination With CD-LD IR to IPX066 Followed by IPX066 Extension Safety Study
The study had three distinct parts and is described as follows: Part 1: To evaluate the dose conversion from CD-LD ER taken alone or in combination with CD-LD IR to IPX066 in subjects with advanced PD To evaluate the utility of…
- Trial name
- NCT01411137
- Testing
- IPX066
- Where
- 8 sites in United States
- Volunteers
- 43 people
- Sponsor
- Impax Laboratories, LLC
Parkinson's Disease (PD), Parkinson Disease 6, Early-Onset
Phase Ⅲ Clinical Trial to Evaluate the Efficacy and Safety of TJ0113 Capsules in Patients With Early-Onset Parkinson's Disease
This study is a randomized, double-blind, multicenter, placebo-controlled Phase III clinical trial designed to evaluate the efficacy, safety, and Pop PK characteristics of TJ0113 Capsules in treating EOPD patients.
- Trial name
- NCT07741045
- Testing
- TJ0113 200mg, TJ0113 400mg
- Where
- 21 sites in China
- Volunteers
- 300 people
- Sponsor
- Hangzhou PhecdaMed Co., Ltd.
Carcinoma, Hepatocellular
Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)
The purpose of this study is to evaluate the efficacy and safety of lenvatinib and pembrolizumab in combination with TACE versus TACE plus oral and intravenous (IV) placebos in participants with incurable, non-metastatic…
- Trial name
- NCT04246177
- Testing
- Lenvatinib, Pembrolizumab, TACE
- Where
- 205 sites in United States, Australia and 25 more
- Volunteers
- 480 people
- Sponsor
- Merck Sharp & Dohme LLC
Parkinson Disease, Mild Cognitive Impairment
Randomized Clinical Trial of Donepezil for the Treatment of Mild Cognitive Impairment in Parkinson's Disease
Phase II, multi-centric, randomized, double-blinded, placebo-controlled, parallel design clinical trial to evaluate the safety, tolerability and efficacy of Donepezil in patients with Mild Cognitive Impairment in Parkinson's…
- Trial name
- NCT05709301
- Testing
- Donepezil Hydrochloride
- Volunteers
- 120 people
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Parkinson's Disease (PD)
Coordinated Reset Deep Brain Stimulation
The study will explore the viability of an alternative/novel programming strategy in Deep Brain Stimulation (DBS) for patients with Parkinson's Disease (PD).
- Trial name
- RESET-DBS (NCT03732898)
- Testing
- Novel Programming (nDBS), Conventional Programming (cDBS)
- Where
- 2 sites in Germany
- Volunteers
- 15 people
- Sponsor
- Boston Scientific Corporation
Parkinson's Disease (PD)
STN-tTIS With Different Intervention Intervals Versus Standard Medical Treatment for Parkinson's Disease
The goal of this clinical trial is to compare the efficacy and safety of different Intervention Intervals of subthalamic nucleus-targeted transcranial temporal interference stimulation (STN-tTIS) in patients with Parkinson…
- Trial name
- NCT07774312
- Testing
- STN-tTIS Once Weekly, STN-tTIS Twice Weekly, STN-tTIS Five Times Weekly
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Ruijin Hospital
Parkinson Disease
Cost of Parkinson's Disease in Hong Kong
The goal of this study is to estimate the cost of disease and falls among people with Parkinson's disease in Hong Kong . There will be no intervention delivered to the participants.
- Trial name
- Burden of PD (NCT05774210)
- Volunteers
- 139 people
- Sponsor
- The Hong Kong Polytechnic University
Parkinson's Disease
Multicenter Placebo Controlled Study to Assess the Effect of Rasagiline on Sleep-wake Disturbances in Patients With Parkinson's Disease
Sleep-wake disturbances (SWD) are frequent in Parkinson's disease (PD) and affect the quality of life of affected patients. Rasagiline is a potent, highly selective, irreversible, second-generation, monoamine oxidase type-B…
- Trial name
- Ras-PDS-1 (NCT01178047)
- Testing
- Rasagiline
- Where
- 2 sites in Switzerland
- Volunteers
- 1 people
- Sponsor
- University of Zurich
Parkinson's Disease
Study of Urate Elevation in Parkinson's Disease, Phase 3
A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial to determine whether oral inosine dosed to moderately elevate serum urate (from ≤5.7 mg/dL to 7.1-8.0 mg/dL) over 2 years slows clinical decline in early…
- Trial name
- SURE-PD3 (NCT02642393)
- Testing
- Inosine
- Where
- 62 sites in United States, Puerto Rico
- Volunteers
- 298 people
- Sponsor
- Michael Alan Schwarzschild
Parkinson Disease, Gait Disorders, Neurologic
External vs Internal-triggered Augmented-reality Visual Cues to Treat Freezing of Gait
Postural instability, freezing-of-gait (FOG), and falls are among the greatest unmet needs in Parkinson disease (PD). FOG eventually affects more than half of people with PD, and is notoriously difficult to treat…
- Conditions
- Parkinson Disease, Gait Disorders, Neurologic, Parkinsonian Disorders, Movement Disorders
- Trial name
- ELIMINATE-FOG (NCT05608915)
- Testing
- No Cue, Conventional Cue, Constant Cue
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- The Cleveland Clinic
Parkinson Disease
PPMI Clinical - Establishing a Deeply Phenotyped PD Cohort
The Parkinson Progression Marker Initiative (PPMI) is a longitudinal, observational, multi-center natural history study to assess progression of clinical features, digital outcomes, and imaging, biologic and genetic markers of…
- Trial name
- PPMI (NCT04477785)
- Where
- 50 sites in United States, Austria and 10 more
- Volunteers
- 4,500 people, healthy volunteers welcome
- Sponsor
- Michael J. Fox Foundation for Parkinson's Research
Parkinson Disease (PD)
The Safety, Feasibility and Efficacy of NouvNeu001 for Parkinson's Disease
This clinical trial is designed to evaluate the safety, tolerability and preliminary efficacy of a single injection of NouvNeu001 (Human Dopaminergic Progenitor Cells Injection) in patients with Parkinson's disease.
- Trial name
- NCT07028632
- Testing
- Human Dopaminergic Progenitor Cells
- Where
- China
- Volunteers
- 30 people
- Sponsor
- iRegene Therapeutics Co., Ltd.
Parkinson Disease (PD)
L-THEANINE AND MEDITERRANEAN DIET ON RBD, GI FUNCTION, AND INFLAMMATION IN PARKINSON'S DISEASE
Parkinson's disease is a progressive neurological disorder associated with severe dopaminergic neuron loss in the substantia nigra pars compacta.
- Trial name
- NCT07682532
- Testing
- Dietary Supplement
- Where
- Turkey (Türkiye)
- Volunteers
- 52 people
- Sponsor
- Medipol University
Advanced Solid Tumors
Study of Quavonlimab (MK-1308) in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001)
This study will assess the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of escalating doses of quavonlimab when used in combination with pembrolizumab in participants with advanced solid tumors.
- Trial name
- NCT03179436
- Testing
- Quavonlimab, Pembrolizumab, Pembrolizumab/Quavonlimab
- Where
- 53 sites in United States, Australia and 14 more
- Volunteers
- 415 people
- Sponsor
- Merck Sharp & Dohme LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.